Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer

Oncology

Volumn 60, Issue 1, 2001, Pages 49-54

  Nishimura, Kazuo ^a   Nonomura, N ^a   Ono, Y ^a   Nozawa, M ^a   Fukui, T ^a   Harada, Y ^a   Imazu, T ^a   Takaha, N ^a   Sugao, H ^b   Miki, T ^c   Okuyama, A ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Mino Municipal Hospital   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Cyclophosphamide; Estramustine; Hormone refractory prostate cancer; UFT

Indexed keywords

CYCLOPHOSPHAMIDE; ESTRAMUSTINE; PROSTATE SPECIFIC ANTIGEN; TEGAFUR; URACIL;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PAIN; CANCER PATIENT; CLINICAL ARTICLE; DRUG TOLERABILITY; HUMAN; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CYCLOPHOSPHAMIDE; ESTRAMUSTINE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TEGAFUR; TREATMENT OUTCOME; URACIL; URINATION;

EID: 17744367405     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055296     Document Type: Article

References (20)

1. Cancer statistics, 1998
2. A controlled trial of leuprolide with and without flutamide in prostate carcinoma
3. Bilateral orchidectomy with or without flutamide for metastatic prostate cancer
4. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?
5. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostate carcinoma
6. Disposition and metabolism of 1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) in humans
7. Oral cyclophosphamide for the management of hormone-refractory prostate cancer
8. Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients
9. Concentration of 5-FU level in the tissue and blood of the patients with breast cancer by preoperative administration of UFT
10. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate
11. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer
12. The assessment of treatment outcomes in metastatic prostate cancer: Changing endpoints
13. Trimetrexate in prostatic cancer: Preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease
14. High dose bicalutamide for androgen independent prostate cancer: Effect of prior hormonal therapy
15. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables
16. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points
17. Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm
18. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer
19. Phase II trial of 96-hour paclitaxel plus estramustine phosphate in metastatic hormone-refractory prostate cancer
20. Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer